Share on StockTwits

Celsion (NASDAQ:CLSN) CEO Michael H. Tardugno purchased 4,000 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were purchased at an average cost of $3.12 per share, for a total transaction of $12,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,521 shares in the company, valued at approximately $232,506. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Paradigm Capital raised their price target on shares of Celsion from $12.50 to $13.50 in a research note on Thursday, July 17th. They now have a “buy” rating on the stock.

Shares of Celsion (NASDAQ:CLSN) traded down 2.50% during mid-day trading on Friday, hitting $3.12. 263,020 shares of the company’s stock traded hands. Celsion has a 1-year low of $2.82 and a 1-year high of $6.6216. The stock has a 50-day moving average of $3.24 and a 200-day moving average of $3.39. The company’s market cap is $53.7 million.

Celsion (NASDAQ:CLSN) last released its earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.32) by $0.06. Analysts expect that Celsion will post $-1.33 EPS for the current fiscal year.

Celsion Corporation (NASDAQ:CLSN) is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer.

Receive News & Ratings for Celsion Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Co and related companies with Analyst Ratings Network's FREE daily email newsletter.